In this study, we examined the use of whole-genome DNA methylation array (WGMA) testing to identify IDH1/IDH2 pathway disruption, through the detection of CIMP, in addition to the characterization of additional molecular alterations that may assist in the classification of glioma tumors. This evidence concerns the gene IDH2 and central nervous system cancer.